SIM-0610 / Simcere - LARVOL DELTA

SIMCERE PHARMA… announced that the Group’s independently developed Bispecific Antibody-Drug Conjugate (BsADC) investigational new drug candidate, SIM0610, had received the Clinical Trial Approval issued by the National Medical Products Administration of China, and is intended to be evaluated in patients with locally advanced or metastatic solid tumors. (iis.aastocks.com)

New trial • Solid Tumor

SCR-A006, an innovative and potential best-in-class EGFR/cMet bispecific antibody-drug conjugate (AACR 2025) - "SCR-A006 also showed good efficacy and was superior to benchmark ADC in amivantamab resistant xenograft models. Taken together, these findings highlight the potential of SCR-A006 as a therapeutic candidate for broad treatment of solid tumors and with a larger therapeutic window than other EGFR/cMET BsADCs. IND enabling studies of SCR-A006 are currently underway, and planned to initiate clinical study in 2025."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR